FluoGuide A/S (STO:FLUO)

Market Cap	529.82M
Revenue (ttm)	591.51K
Net Income (ttm)	-44.49M
Shares Out	13.62M
EPS (ttm)	-3.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,195
Average Volume	7,263
Open	38.90
Previous Close	38.90
Day's Range	38.10 - 40.00
52-Week Range	29.10 - 58.60
Beta	1.61
RSI	49.74
Earnings Date	May 28, 2025

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK